Spotlight – scratching the surface of the urticaria pipeline
Catalysts from several late-stage projects including those from Astrazeneca, Sanofi, Allakos and Celldex aim to shake up the market.
More, but slower, medtech approvals
If the second half maintains the pace, 2023 could see the most device approvals for a decade.
Go or no go? Decision day looms for Eisai and Biogen
Leqembi seeks full approval, while Takeda hopes for a dengue green light and Verrica looks to break its streak of bad luck.
Lilly goes cellular for $34m
And conveniently, Celltrans blazes a trail for cell therapies in diabetes.